Re: Colorectal cancer life expectancy

A new neuroimmunotherapeutic strategy of subcutaneous low-dose
interleukin-2 plus the long-acting opioid antagonist naltrexone in
metastatic cancer patients progressing on interleukin-2 alone.Lissoni
P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.
Division of Radiation Oncology, S. Gerardo Hospital, Monza, Milan,
Italy.

OBJECTIVES: Recent advances in knowledge of Psychoneuroimmunology have
shown that several neuroactive substances, including neurohormones and
neuropeptides, may exert immunomodulatory effects. However, despite
the great variety of potential neuroimmune interactions, at present we
may recognize two major neuroendocrine systems exerting a
physiological neuroimmunomodulatory function, consisting of the pineal
gland and the brain opioid system, provided by immunostimulatory and
immunosuppressive effects, respectively. Recent in human studies have
demonstrated the possibility to amplify the biological activity of
IL-2, the major anticancer cytokine, by pineal indoles. MATERIALS &
METHODS: The present study was carried out to draw some preliminary in
human results on the possible immunomodulatory effects of the
inhibition of the brain opioid activity by a long-acting opioid
antagonist, naltrexone (NTX). The study was performed in 10 metastatic
renal cell cancer patients, who had progressed on a previous
immunotherapeutic cycle with IL-2 alone. Patients were treated with
the same doses of IL-2 (6 million lU/day subcutaneously for 6 days/
week for 4 weeks) plus an oral administration of NTX at a dose of 100
mg every 2 days. RESULTS: The clinical response consisted of a partial
response in 1 and a stable disease in 5 patients, whereas the other 4
patients progressed. Therefore, the percent of non-progressive disease
was 6/10 (60%). Moreover, mean lymphocyte increase achieved during
IL-2 plus NTX was significantly higher (P<0.05) than that obtained
during the previous treatment with IL-2 alone. CONCLUSIONS: This study
shows that a blockade of the brain opioid system, which plays a
physiological immunosuppressive role, may improve the anticancer
effects of IL-2 in humans.

PMID: 12080288 [PubMed - indexed for MEDLINE]






On May 28, 9:11 pm, J <xnswex@nalid;"no> wrote:
cmarta wrote:
1: Related Articles, LinksLissoni P, Malugani F, Malysheva O, Kozlov
V, Laudon M, Conti A, Maestroni G.

Neuroimmunotherapy of untreatable metastatic solid tumors with
subcutaneous low-dose interleukin-2, melatonin and naltrexone:
modulation of interleukin-2-induced antitumor immunity by blocking the
opioid system.
Neuro Endocrinol Lett. 2002 Aug;23(4):341-4.
PMID: 12195238 [PubMed - indexed for MEDLINE]2: Related Articles,
LinksLissoni P, Malugani F, Bordin V, Conti A, Maestroni G, Tancini G.

A new neuroimmunotherapeutic strategy of subcutaneous low-dose
interleukin-2 plus the long-acting opioid antagonist naltrexone in
metastatic cancer patients progressing on interleukin-2 alone.
Neuro Endocrinol Lett. 2002 Jun;23(3):255-8.
PMID: 12080288 [PubMed - indexed for MEDLINE]3: Related Articles,
LinksLissoni P, Meregalli S, Fossati V, Barni S, Tancini G, Barigozzi
P, Frigerio F.

Radioendocrine therapy of brain tumors with the long acting opioid
antagonist naltrexone in association with radiotherapy.
Tumori. 1993 Jun 30;79(3):198-201.
PMID: 8236504 [PubMed - indexed

And how was life expectancy affected, if at all?
J- Hide quoted text -

- Show quoted text -

.